–Surface acquisition and potential toripalimab approval will transform Coherus into an I-O company with multiplenext-generationimmunotherapies in clinical development funded bygrowing revenues –
– Toripalimab plus chemotherapy resulted in a 37% reduction in the risk of death, HR=0.63, versus chemotherapy alone, in nasopharyngeal carcinoma patients.
– Toripalimab plus chemotherapy resulted in a 37% reduction in the risk of death, HR=0.63, versus chemotherapy alone, in nasopharyngeal carcinoma patients – – No treatments are. | June 5, 2023
– UDENYCA® AI is the only pegfilgrastim prefilled autoinjector product presentation available in the U.S. that can be administered either in-office or at-home – –. | May 22, 2023